Cervical cancer vaccine: Who needs it, how it works

Who needs the cervical cancer vaccine? How many doses? Can boys be vaccinated, too? What about side effects? Get answers to these questions and more.

By Mayo Clinic staff
Photo of Bobbie Gostout, M.D.
Bobbie Gostout, M.D.

Most cervical cancers are caused by the sexually transmitted infection human papillomavirus (HPV). Widespread HPV immunization, however, could reduce the impact of cervical cancer worldwide. Here, Bobbie Gostout, M.D., an HPV infection expert and gynecologic surgeon at Mayo Clinic, Rochester, Minn., discusses the cervical cancer vaccine.

What does the cervical cancer vaccine do?

Various strains of HPV, which spread through sexual contact, cause most cases of cervical cancer. Two cervical cancer vaccines have Food and Drug Administration (FDA) approval in the U.S. — Gardasil and Cervarix. Both vaccines can prevent most cases of cervical cancer if given before a girl or woman is exposed to the virus.

In addition, both can prevent most vaginal and vulvar cancer in women, and Gardasil can prevent genital warts in women and men.

Who is the cervical cancer vaccine for and when should it be given?

The cervical cancer vaccine is recommended for girls and boys ages 11 to 12, although it may be given as early as age 9. It's important for boys and girls to receive the vaccine before they have sexual contact and are exposed to HPV. Once infected with HPV, the vaccine may not be as effective.

If not fully vaccinated at ages 11 to 12, the Centers for Disease Control and Prevention (CDC) recommends that girls and women through age 26 and boys and men through age 21 receive the vaccine. However, men may receive the HPV vaccine through age 26 if desired.

Both vaccines are given as a series of three injections over a six-month period. The second dose is given one to two months after the first dose, and the third dose is given six months after the first dose.

The cervical cancer vaccine isn't recommended for pregnant women or people who are moderately or severely ill. Tell your doctor if you have any severe allergies, including an allergy to yeast or latex.

Why are three doses of the cervical cancer vaccine needed?

Researchers don't yet know what antibody levels provide adequate protection from HPV. In early clinical trials, researchers observed that women's antibody levels continued to increase with each of the three doses of the vaccine. Since antibody levels inevitably fall once you stop getting a vaccine, it makes sense to start with high antibody levels and attempt to get the greatest HPV protection for the longest possible time — years or even decades.

Over time, however, researchers may find that three doses of the vaccine aren't necessary — or that a booster shot is needed years later.

Does the cervical cancer vaccine offer benefits if you're already sexually active?

Yes. In clinical trials, Gardasil and Cervarix were effective in groups of sexually active women age 26 or younger, some of whom had already been infected with one or more types of HPV. However, Gardasil and Cervarix only protect you from specific strains of HPV to which you haven't been exposed. The more sexual partners you've had, the greater your chance of having been exposed to multiple types of HPV.

Next page
(1 of 2)
References
  1. Recommended immunization schedule for persons aged 7-18 years — United States, 2010. Centers for Disease Control and Prevention. http://www.cdc.gov/vaccines/recs/schedules/downloads/child/2010/10_7-18yrs-schedule-pr.pdf. Accessed Oct. 8, 2010.
  2. Garland SM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine. 2007;356:1928.
  3. Reports of health concerns following HPV vaccination. Centers for Disease Control and Prevention. http://www.cdc.gov/vaccinesafety/Vaccines/HPV/gardasil.html. Accessed Oct. 8, 2010.
  4. Detailed guide: Cervical cancer: What are the risk factors for cervical cancer? American Cancer Society. http://www.cancer.org/Cancer/CervicalCancer/DetailedGuide/cervical-cancer-risk-factors. Accessed Oct. 8, 2010.
  5. Human papillomavirus (HPV) vaccines. National Cancer Institute. http://www.cancer.gov/cancertopics/factsheet/Prevention/HPV-vaccine. Accessed Oct. 7, 2010.
  6. Dillner J, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: Randomised controlled trial. British Medical Journal. 2010;341:c3493.
  7. HPV (human papillomavirus) vaccine: Gardasil. What you need to know. Centers for Disease Control and Prevention. http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-hpv-gardasil.pdf. Accessed Oct. 8, 2010.
  8. HPV (human papillomavirus) vaccine: Cervarix. What you need to know. Centers for Disease Control and Prevention. http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-hpv-cervarix.pdf. Accessed Oct. 8, 2010.
  9. Gardasil vaccine safety: Information from FDA and CDC on the safety of Gardasil vaccine. U.S. Food and Drug Administration. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/ucm179549.htm. Accessed Oct. 8, 2010.
  10. Recommended adult immunization schedule: United States, 2010. Centers for Disease Control and Prevention. http://www.cdc.gov/vaccines/recs/schedules/downloads/adult/2010/adult-schedule.pdf. Accessed Oct. 7, 2010.
  11. Castle P, et al. Recommendations for the use of human papillomavirus vaccines. http://www.uptodate.com/home/index.html. Accessed Oct. 12, 2010.
  12. Castle P, et al. Clinical trials of human papillomavirus vaccines. http://www.uptodate.com/home/index.html. Accessed Oct. 12, 2010.
  13. What you need to know about cervical cancer: Symptoms. National Cancer Institute. http://www.cancer.gov/cancertopics/wyntk/cervix/page5. Accessed Oct. 12, 2010.
  14. Hoecker JL (expert opinion). Mayo Clinic, Rochester, Minn. Oct. 13, 2010.
  15. Gostout BS (expert opinion). Mayo Clinic, Rochester, Minn. Oct. 29, 2010.
  16. Centers for Disease Control and Prevention, et al. Recommendations on the use of quadrivalent human papillomavirus vaccine in males — Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports. 2011:60;1705.
WO00120 Jan. 20, 2012

© 1998-2013 Mayo Foundation for Medical Education and Research (MFMER). All rights reserved. A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.com," "EmbodyHealth," "Enhance your life," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.

  • Reprints
  • Print

  • Share on:

  • Email

Advertisement


Text Size: smaller largerlarger